Literature DB >> 8943378

CD11b+CD28-CD4+ human T cells: activation requirements and association with HLA-DR alleles.

A Chapman1, S J Stewart, G T Nepom, W F Green, D Crowe, J W Thomas, G G Miller.   

Abstract

Engagement of CD28 induces a major costimulatory pathway required by many CD4+ T cells in addition to activation via the TCR. In the absence of signals provided by CD28, ligation of the TCR alone can induce anergy or apoptosis in CD28+ cells. However, we report here characterization of a distinct subset of CD4+ T cells that are CD28-. Three autoreactive CD4+ human T cell clones that could be activated to produce IL-2 and proliferate by anti-CD3 alone were found to lack expression of CD28. CD28- clones that were activated with anti-CD3 alone were not anergic to restimulation via CD3. The presence of CD28-CD4+ T cells was verified in peripheral blood, and their frequency ranged from 0% to >22% of CD4+ T cells in different individuals. The percentage of CD28-CD4+ T cells in the peripheral blood of 57 individuals was significantly correlated with specific class II MHC alleles. Persons with HLA-DRB1*0401 and DR1 alleles had significantly higher numbers of CD28- T cells, while individuals with HLA-DR2(15) had significantly fewer CD28-CD4+ T cells than the mean. Like the CD28- clones, CD28-CD4+ T cells isolated from peripheral blood proliferated upon CD3 cross-linking in the absence of costimulation. The finding that CD28-CD4+ T cells resist induction of anergy following engagement of the TCR in the absence of conventional costimulation demonstrates one mechanism by which autoreactive T cells can escape processes that censor self-reactivity. The MHC associations observed suggest a relationship with autoimmunity and loss of self-tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943378

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Antigen-presenting cells in rheumatoid arthritis.

Authors:  R Thomas
Journal:  Springer Semin Immunopathol       Date:  1998

2.  Association between HLA-DRB1, HLA-DRQB1 alleles, and CD4(+)CD28(null) T cells in a Chinese population with coronary heart disease.

Authors:  Wenjie Sun; Ying Cui; Lihui Zhen; Lijuan Huang
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

3.  Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells.

Authors:  S Kottilil; J Gamberg; I Bowmer; J Trahey; C Howley; M Gallant; M Grant
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 4.  Immune aging and rheumatoid arthritis.

Authors:  Jorg J Goronzy; Lan Shao; Cornelia M Weyand
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

5.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes.

Authors:  C M Weyand; P A Klimiuk; J J Goronzy
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity.

Authors:  R Giscombe; S Nityanand; N Lewin; J Grunewald; A K Lefvert
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

Review 8.  Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.

Authors:  Tin Kyaw; Karlheinz Peter; Yi Li; Peter Tipping; Ban-Hock Toh; Alex Bobik
Journal:  Br J Pharmacol       Date:  2017-06-13       Impact factor: 8.739

Review 9.  Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2003-08-08       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.